Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dodwell

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
BMJ Open|December 19, 2022
Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasiaKaren Clements, David Dodwell, Bridget Hilton, et al.
British Journal of Cancer|October 12, 2022
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane ProjectAbeer M Shaaban, Bridget Hilton, Karen Clements, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2015
Addressing overtreatment of screen detected DCIS; the LORIS trialAdele Francis, Jeremy Thomas, Lesley Fallowfield, et al.
BMJ Open|April 20, 2024
Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT projectShelley Potter, Kerry Avery, Rosina Ahmed, et al.
Annals of Surgical Oncology|November 30, 2017
Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) TrialDaniel Rea, Adele Francis, Matthew Wallis, et al.
American Journal of Ophthalmology|May 12, 2009
Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularizationAhmad M Mansour, J Fernando Arevalo, Focke Ziemssen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2017
Long-Term Follow-Up of the Intergroup Exemestane StudyJames P Morden, Isabel Alvarez, Gianfilippo Bertelli, et al.
Breast (Edinburgh, Scotland)|October 23, 2012
Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumoursEmad A Rakha, Puay Hoon Tan, Abeer Shaaban, et al.
The Lancet. Oncology|August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialStephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trialMarion Procter, Thomas M Suter, Evandro de Azambuja, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
BMJ Open|December 19, 2022
Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasiaKaren Clements, David Dodwell, Bridget Hilton, et al.
British Journal of Cancer|October 12, 2022
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane ProjectAbeer M Shaaban, Bridget Hilton, Karen Clements, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2015
Addressing overtreatment of screen detected DCIS; the LORIS trialAdele Francis, Jeremy Thomas, Lesley Fallowfield, et al.
BMJ Open|April 20, 2024
Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT projectShelley Potter, Kerry Avery, Rosina Ahmed, et al.
Annals of Surgical Oncology|November 30, 2017
Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) TrialDaniel Rea, Adele Francis, Matthew Wallis, et al.
American Journal of Ophthalmology|May 12, 2009
Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularizationAhmad M Mansour, J Fernando Arevalo, Focke Ziemssen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2017
Long-Term Follow-Up of the Intergroup Exemestane StudyJames P Morden, Isabel Alvarez, Gianfilippo Bertelli, et al.
Breast (Edinburgh, Scotland)|October 23, 2012
Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumoursEmad A Rakha, Puay Hoon Tan, Abeer Shaaban, et al.
The Lancet. Oncology|August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialStephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trialMarion Procter, Thomas M Suter, Evandro de Azambuja, et al.
Pageof 12